查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球血癌藥物市場 - 2023-2030年
市場調查報告書
商品編碼
1290434

全球血癌藥物市場 - 2023-2030年

Global Blood Cancer Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球血癌藥物市場規模在2022年達到630億美元，預計到2030年將見證有利可圖的成長，達到1135億美元。在2023-2030年的預測期內，全球血癌藥物市場預計將呈現7.8%的複合成長率。市場的主要趨勢是免疫療法的快速發展。

例如，2023年4月，下一代精準腫瘤學公司Strata Oncology, Inc.宣布推出Strata Select，這是一種針對晚期癌症患者的首次分子分析測試。

這項新的診斷測試的特點是免疫療法反應得分，這是一種新型的多變量預測生物標記算法，用於預測抗PD-1/PD-L1檢查點抑製劑免疫療法的益處。血癌藥物包括不同的治療干預措施，包括化療、靶向治療、免疫治療和支持性護理藥物，旨在專門針對並抑制血液和骨髓中的癌細胞生長。

這些藥物旨在破壞異常的細胞過程，抑制癌細胞增殖，誘導細胞凋亡，並恢復正常的血細胞生成和功能。

血癌藥物市場的驅動因素包括：血癌發病率的增加、癌症研究的進步、靶向治療的發展、免疫治療和個性化醫療。

例如，2023年5月，Amneal Pharmaceuticals, Inc.宣布推出FYLNETRA的商業化，這是一種參考Neulasta的生物學名藥，採用預裝單劑量注射器。 FYLNETRA用於治療接受化療的病人普遍出現的中性粒細胞減少症。

市場動態

血癌的發病率不斷增加

血癌發病率的增加是在預測期內推動市場佔有率的主要因素。血癌，特別是某些類型的血癌，如白血病、淋巴瘤和多發性骨髓瘤，更常在老年人中診斷出來。隨著全球人口持續老齡化，血癌的總體發病率增加。

接觸某些環境因素和選擇不健康的生活方式會增加患血癌的風險。環境因素包括暴露於輻射、某些化學品、殺蟲劑和工業污染物。不健康的行為，如吸煙、過度飲酒和久坐不動的生活方式，也會促使血癌的發生。

治療的高成本和副作用

由於涉及廣泛的研究和開發工作，以及製造和測試過程的複雜性，血癌藥物往往有一個高價格標籤。這些藥物的成本會給病人、醫療系統和付款人帶來巨大的經濟負擔。高昂的治療費用會影響市場成長，阻礙病人獲得血癌藥物。

血癌藥物會引起各種不良反應，包括疲勞、噁心、嘔吐、脫髮、免疫抑制和器官毒性。這些副作用會嚴重影響患者的生活品質和治療依從性。管理副作用和製定支持性護理措施是改善患者療效和市場對血癌藥物接受度的重要考慮。

COVID-19影響分析

COVID-19大流行病深刻地影響了醫療保健行業，包括血癌藥物市場。血癌患者被認為是脆弱的，因為他們的免疫系統受到損害，出現COVID-19嚴重後果的風險更高。因此，病人的管理策略已被修改，以盡量減少與病毒的接觸。

一些與血癌藥物有關的研究活動可能暫時被取消優先權，或被重新定向到與COVID-19有關的項目。這種研究重點的轉移可能會影響血液腫瘤藥物市場的藥物開發和創新速度。

俄烏衝突分析

俄烏衝突對血癌藥物市場產生了重大影響。衝突可能會擾亂機構和製藥公司的研究和開發合作。在藥物發現、臨床試驗和科學交流方面的合作努力可能會受到阻礙，影響創新和開發新血癌藥物的步伐。

俄羅斯和烏克蘭之間的衝突可能會影響血癌藥物市場的國際合作和投資。由於地緣政治風險和不確定性，公司和投資者可能會謹慎對待這些市場，有可能促使投資和合作的放緩。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按癌症類型分析
  • 按治療類型簡述
  • 按給藥途徑分類
  • 按終端用戶分類
  • 按地區分類

第4章：動態變化

  • 影響因素
    • 驅動因素
      • 血癌的發病率不斷上升
      • 靶向治療和免疫治療的發展
    • 限制因素
      • 治療費用高
      • 與治療相關的副作用
    • 機會
      • 癌症研究的進步
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • 後COVID-19或未來的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第七章：按癌症類型

  • 白血病
  • 骨髓瘤
  • 非霍奇金淋巴瘤
  • 霍奇金淋巴瘤

第8章：按治療類型分類

  • 化療
  • 放射治療
  • 免疫治療
  • 靶向治療
  • 其他療法

第九章：按給藥途徑分類

  • 口服
  • 靜脈注射
  • 其他途徑

第十章：按終端用戶分類

  • 醫院
  • 專業診所
  • 非住院手術中心
  • 其他

第十一章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第十二章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 合併和收購分析

第十三章：公司簡介

  • Amgen Inc.
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • AstraZeneca Plc
  • Takeda Pharmaceutical Company Ltd
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Bristol-Myers Squibb Company
  • Gilead Sciences Inc.
  • Daiichi Sankyo Company Ltd
  • UCB SA

第十四章：附錄

簡介目錄
Product Code: PH3416

Market Overview

The Global Blood Cancer Drugs Market size reached US$ 63 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 113.5 billion by 2030. The Global Blood Cancer Drugs Market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. The key market trend is the rapid advancements of immunotherapies.

For instance, in April 2023, Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer.

The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Blood cancer drugs encompass diverse therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies, and supportive care medications, designed to specifically target and inhibit the growth of cancerous cells in the blood and bone marrow.

These drugs aim to disrupt abnormal cellular processes, suppress cancer cell proliferation, induce apoptosis, and restore normal blood cell production and function.

The blood cancer drugs market is driven by factors such as the increasing prevalence of blood cancers, advancements in cancer research, development of targeted therapies, immunotherapies, and personalized medicine.

For instance, in May 2023, Amneal Pharmaceuticals, Inc. announced the commercial launch of FYLNETRA, a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy.

Market Dynamics

Increasing prevalence of blood cancers

The increasing prevalence of blood cancers is the major factor driving the market share during the forecast period. Blood cancers, particularly certain types such as leukemia, lymphoma, and multiple myeloma, are more commonly diagnosed in older individuals. As the global population continues to age, the overall incidence of blood cancers increases.

Exposure to certain environmental factors and unhealthy lifestyle choices can increase the risk of developing blood cancers. Environmental factors include exposure to radiation, certain chemicals, pesticides, and industrial pollutants. Unhealthy behaviors like smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to the development of blood cancers.

High cost and side effects of treatment

Blood cancer drugs often come with a high price tag due to the extensive research and development efforts involved and the complexity of manufacturing and testing processes. The cost of these drugs can pose a significant financial burden on patients, healthcare systems, and payers. The high cost of treatment can impact market growth and hinder patient access to blood cancer drugs.

Blood cancer drugs can cause various adverse effects, including fatigue, nausea, vomiting, hair loss, immunosuppression, and organ toxicity. These side effects can significantly impact patients' quality of life and treatment adherence. Managing side effects and developing supportive care measures are important considerations in improving patient outcomes and market acceptance of blood cancer drugs.

COVID-19 Impact Analysis

The COVID-19 pandemic has profoundly impacted the healthcare industry, including the blood cancer drugs market. Blood cancer patients are considered vulnerable due to their compromised immune systems and higher risk of severe COVID-19 outcomes. As a result, patient management strategies have been modified to minimize exposure to the virus.

Some research activities related to blood cancer drugs may have been temporarily deprioritized or redirected towards COVID-19-related projects. This shift in research focus may impact the pace of drug development and innovation in the blood cancer drugs market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has significantly impacted the blood cancer drugs market. The conflict may disrupt research and development collaboration in institutions and pharmaceutical companies. Collaborative efforts in drug discovery, clinical trials, and scientific exchange may be hampered, impacting the pace of innovation and development of new blood cancer drugs.

The conflict between Russia and Ukraine may impact international collaborations and investments in the blood cancer drugs market. Companies and investors may approach these markets with caution due to geopolitical risks and uncertainties, potentially leading to a slowdown in investments and collaborations.

Segment Analysis

The Global Blood Cancer Drugs Market is segmented based on cancer type, therapy type, route of administration, End User, and region.

Based on cancer type, the leukemia segment is expected to dominate the market share

The leukemia market will hold 35.8% of the global blood cancer drugs market share in 2022. Leukemia has been the subject of extensive research and development efforts in the field of blood cancer drugs. Significant advancements have been made in understanding the molecular basis of different leukemia subtypes, leading to the development of targeted therapies and immunotherapies.

For instance, in May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older.

Geographical Analysis

North America holds the largest market share due to the presence of key players and advanced healthcare infrastructure

North America holds the 41.3% market share for the blood cancer drugs market in 2022 due to the presence of key players and advanced healthcare infrastructure in the region. North America boasts advanced healthcare infrastructure, including well-established hospitals, research institutions, and oncology centers.

The region has a robust healthcare system that facilitates access to diagnosis, treatment, and follow-up care for blood cancer patients. The availability of state-of-the-art medical facilities, advanced diagnostic technologies, and specialized healthcare professionals supports the demand for blood cancer drugs and drives market growth.

Competitive Landscape

The major global players in the market include: Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.

Why Purchase the Report?

  • To visualize the Global Blood Cancer Drugs Market segmentation based on cancer type, therapy type, route of administration, End User, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of blood cancer drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Blood Cancer Drugs Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Therapy Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of blood cancers
      • 4.1.1.2. Development of targeted therapies and immunotherapies
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of treatment
      • 4.1.2.2. Side effects associated with treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Advancements in cancer research
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Leukemia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Myeloma
  • 7.4. Non-Hodgkin Lymphoma
  • 7.5. Hodgkin Lymphoma

8. By Therapy Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 8.1.2. Market Attractiveness Index, By Therapy Type
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Radiation Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Amgen Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. AstraZeneca Plc
  • 13.3. Takeda Pharmaceutical Company Ltd
  • 13.4. Bayer AG
  • 13.5. Celgene Corporation
  • 13.6. Eli Lilly
  • 13.7. Bristol-Myers Squibb Company
  • 13.8. Gilead Sciences Inc.
  • 13.9. Daiichi Sankyo Company Ltd
  • 13.10. UCB SA

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us